Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.66 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.55 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8469613 | 1.00 | FOLH1 (0.66) | FOLH1GRM3CPA3 | |
| SCHEMBL5134379 | 0.88 | FOLH1 (0.65) | FOLH1GRM3CPA3 | |
| SCHEMBL6381374 | 0.84 | FOLH1 (0.58) | FOLH1CPA3 | |
| SCHEMBL5134212 | 0.81 | FOLH1 (0.62) | FOLH1GRM3CPA3 | |
| Toluene SCHEMBL6380394 | 0.80 | GRM3 (0.60) | FOLH1GRM3 | |
| SCHEMBL8052865 | 0.80 | FOLH1 (1.00) | FOLH1GRM3CPA3 | |
| SCHEMBL5052894 | 0.79 | CPA3 (0.71) | FOLH1GRM3CPA3 | |
| SCHEMBL12145183 | 0.79 | GRM3 (0.68) | FOLH1GRM3CPA3 | |
| SCHEMBL25448705 | 0.79 | ALDH1A1 (0.53) | FOLH1CPA3 | |
| SCHEMBL21430281 | 0.79 | ALDH1A1 (0.53) | FOLH1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093453-B1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1571141-A2 | Naaladase inhibitors useful as pharmaceutical compounds and compositions | GUILFORD PHARMACEUTICALS INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | JACKSON PAUL F (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-20030013687-A1 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458775-B1 | N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) INHIBITORS ENZYME ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH INHIBITORS, AND METHODS OF THEIR USE TO INHIBIT NAALADASE ENZYME ACTIVITY, THEREBY EFFECTING NEURONAL | GUILFORD PHARMACEUTICAL INC. | 2002-10-01 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1202717-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6376478-B1 | N-ACETYLATED (ALPHA)-LINKED ACIDIC DIPEPTIDASE INHIBITOR; BLOCKS RELEASE OF GLUTAMTE PRE-SYNAPTICALLY FOR REDUCED TOXICITY | GUILFORD PHARMACEUTICALS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6228888-B1 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1093453-A1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001001974-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6071965-A | TO INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY AND TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | FOLH1 56/4885GRM3 3659/4885CPA3 193/4885 |
| US-20030013687-A1 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | GRIN1, GRIN2A, GRIN2B | FOLH1 224/4885GRM3 47/4885CPA3 2557/4885 |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | NAALAD2, DNPEP, NAAA | FOLH1 22/4885GRM3 305/4885CPA3 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.